UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

Journal of hematology and oncology, 2019-12, Vol.12 (1), p.141-141, Article 141

2019

Volltextzugriff (PDF)

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas

Scientific reports, 2021-10, Vol.11 (1), p.21133-8, Article 21133

2021

Volltextzugriff (PDF)

Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

Nature biotechnology, 2017-01, Vol.35 (1), p.35-37

2017

Volltextzugriff (PDF)

Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A

Human gene therapy, 2018-10, Vol.29 (10), p.1183-1201

2018

Volltextzugriff (PDF)

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

Oncoimmunology, 2018-03, Vol.7 (3), p.e1407898-e1407898

2018

Volltextzugriff (PDF)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity

Nature communications, 2023-07, Vol.14 (1), p.4206-4206, Article 4206

2023

Volltextzugriff (PDF)

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials

Oncoimmunology, 2022-12, Vol.11 (1), p.2057012-2057012

2022

Volltextzugriff (PDF)

The Immune Response to the fVIII Gene Therapy in Preclinical Models

Frontiers in immunology, 2020-04, Vol.11, p.494

2020

Volltextzugriff (PDF)

Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy

PloS one, 2013, Vol.8 (1), p.e51805

2013

Volltextzugriff (PDF)

Directing the migration of serum-free, ex vivo -expanded Vγ9Vδ2 T cells

Frontiers in immunology, 2024-02, Vol.15, p.1331322-1331322

2024

Volltextzugriff (PDF)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII

Frontiers in immunology, 2022-12, Vol.13, p.954984

2022

Volltextzugriff (PDF)

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Frontiers in immunology, 2023, Vol.14, p.1294555-1294555

2023

Volltextzugriff (PDF)

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

Frontiers in immunology, 2021-06, Vol.12, p.697602-697602

2021

Volltextzugriff (PDF)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

Oncoimmunology, 2019, Vol.8 (8), p.1593804-1593804

2019

Volltextzugriff (PDF)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers

Molecular therapy. Oncolytics, 2023-06, Vol.29, p.145-157

2023

Volltextzugriff (PDF)

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A

Molecular therapy. Methods & clinical development, 2018-06, Vol.9, p.57-69

2018

Volltextzugriff (PDF)

Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy

Human gene therapy, 2012-07, Vol.23 (7), p.711-721

2012

Volltextzugriff (PDF)

Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette

Molecular therapy. Methods & clinical development, 2021-12, Vol.23, p.98-107

2021

Volltextzugriff (PDF)

Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC

Experimental hematology, 2011-12, Vol.39 (12), p.1124-1135.e4

2011

Volltextzugriff (PDF)

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII

Molecular therapy. Methods & clinical development, 2021-06, Vol.21, p.710-727

2021

Volltextzugriff (PDF)

Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A

Molecular therapy, 2009-07, Vol.17 (7), p.1145-1154

2009

Volltextzugriff (PDF)

Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy

Frontiers in medicine, 2020-11, Vol.7, p.588453-588453

2020

Volltextzugriff (PDF)

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Blood, 2022-01, Vol.139 (4), p.523-537

2022

Volltextzugriff (PDF)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A

Molecular therapy. Methods & clinical development, 2020-06, Vol.17, p.465-477

2020

Volltextzugriff (PDF)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery

Molecular therapy. Methods & clinical development, 2014-01, Vol.1 (C), p.14036-14036, Article 14036

2014

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(128)

Publikationsform

Artikel
(143)

Sprache

Englisch
(143)

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(72)
Humans
(50)
Gene Therapy
(37)
Animals
(35)
Mice
(29)
Medicine, Research & Experimental
(25)
Research & Experimental Medicine
(25)
Biotechnology & Applied Microbiology
(19)
Biochemistry & Molecular Biology
(15)
Genetics & Heredity
(15)
Hematology
(14)
Hemophilia
(14)
Biological And Medical Sciences
(13)
Cell Line
(13)
Factor Viii - Genetics
(13)
Hemophilia A - Therapy
(12)
Kinetics
(12)
Medical Sciences
(12)
Immunotherapy
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas

Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials

The Immune Response to the fVIII Gene Therapy in Preclinical Models

Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy

Directing the migration of serum-free, ex vivo -expanded Vγ9Vδ2 T cells

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A

Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy

Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette

Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII

Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A

Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery

Suchergebnisse filtern